<![CDATA[DURGA-1 Trial Shows Encouraging Results With Novel Multiple Myeloma Agent]]>
At the 2026 Tandem Meetings, Shambavi Richard, MD, shared data from the phase 1b/2 DURGA-1 trial (NCT05850234) showing early and deep responses with AZD0120, a novel BCMA/CD19 dual-targeting cellular therapy, among patients with relapsed/ …